|
23andme Holding Co (NASDAQ: ME) |
|
23andme Holding Co
ME's Fundamental analysis
Select the Comparisons :
|
|
Select the Ratio:
|
|
|
23andme Holding Co's sales fell
by -12.71 % in II. Quarter 2024 from the same quarter a year ago.
Ranking at No. 2263
Major Pharmaceutical Preparations industry recorded
growth of revenues by 9.75 %
23andme Holding Co net loss decreased from $-75 millions, to $-59 millions in II. Quarter 2024,
• More on ME's Growth
|
|
23andme Holding Co realized a net loss in trailing twelve months.
23andme Holding Co realized cash reduction of $ -100.07 per share in trailing twelve-month period. |
Company |
- |
PE TTM
|
Industry |
- |
PE TTM
|
|
Company's Price to Sales ratio is at 0.02.
Major Pharmaceutical Preparations industry's Price to Sales ratio is at 5.01.
• More on ME's Valuation
|
|
|
|
|
23andme Holding Co realized net loss in trailing twelve months.
23andme Holding Co realized cash outflow of $ -100.07per share in trailing twelve-month period. |
Company |
- |
PE TTM
|
Industry |
- |
PE TTM
|
|
Company's Price to Sales ratio is at 0.02.
Major Pharmaceutical Preparations industry's Price to Sales ratio is at 5.01.
23andme Holding Co Price to Book Ratio is at 0.05 lower than Industry Avg. of 77.59. and higher than S&P 500 Avg. of 0.01
• More on ME's Valuation
|
|
|
|
CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.
Copyright © 2025 CSIMarket, Inc. All rights
reserved.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com